Cera’s 300 Billion Data Points to Accelerate Global Medical Research and Healthcare AI

Key Takeaways

• 300 billion data points from 2.5 M monthly home visits.
• Real‑world data fuels AI for early health deterioration alerts.
• Partnerships give pharma access to anonymised longitudinal home‑care data.
• AI agents improve care coordination and reduce admin workload.
• Dataset supports research on dementia, neurological and chronic diseases.

Summary

Cera, Europe’s leading digital‑first home‑healthcare provider, announced it has surpassed 300 billion data points collected from more than 2.5 million patient visits each month. The dataset records symptoms, mobility changes, medication responses, nutrition, mood and behavioural signals, creating one of the world’s most comprehensive real‑world health records outside clinical settings. Cera is using this trove to power AI agents, predictive analytics and robotics while offering anonymised insights to pharmaceutical and life‑science partners for research on dementia, neurological and chronic diseases. The milestone underpins Cera’s strategy to accelerate AI‑driven care, improve outcomes and support drug development.

Pulse Analysis

The aging population across Europe is driving demand for care that can be delivered safely at home. Cera’s digital platform captures granular health signals during each visit, turning routine observations into a massive longitudinal dataset. By aggregating billions of data points outside traditional clinical environments, the company creates a real‑world evidence base that reflects daily life, medication adherence, and subtle functional changes—information that is often missing from hospital records but critical for understanding disease trajectories.

Cera’s AI engine leverages this data to develop predictive models that flag early signs of deterioration, enabling clinicians to intervene before conditions worsen. The technology also automates care coordination, documentation and workforce scheduling, reducing the administrative burden on nurses and caregivers. As the dataset expands, machine‑learning algorithms become more precise, supporting personalized care plans, proactive alerts and even robotic assistance. This AI‑driven efficiency not only improves patient outcomes but also addresses staffing shortages by allowing frontline teams to focus on direct care rather than paperwork.

Beyond patient care, the anonymised dataset is a goldmine for pharmaceutical and life‑science researchers seeking real‑world evidence. Partnerships with firms such as Akrivia Health and Promptly Health give drug developers access to longitudinal health trends that can accelerate clinical trial design, validate therapeutic efficacy and inform regulatory submissions. By bridging home‑care observations with AI analytics, Cera is positioning itself at the nexus of healthcare delivery and medical research, promising faster innovation cycles and more effective treatments for chronic and neuro‑degenerative diseases.